Review of National Gene Technology Scheme - Online Submissions

Closed 18 Dec 2017

Opened 6 Nov 2017


Phase 2 Consultation is now open.

This public consultation process commenced in July 2017 with the release of a Background paper.  Initial consultations were conducted with stakeholders through an online submission process. The feedback obtained from this process has provided a range of insights, and issues, and these have informed the development of the Consultation Paper.

With the release of this consultation paper, stakeholders are invited to provide their feedback on the insights and issues captured from Phase 1 Consultation.

Why We Are Consulting

Using the consultation paper to inform, this online submission has been developed to offer stakeholders the opportunity to express their opinion in response to a series of questions presented.

Responses to Phase 1 submissions have highlighted many issues, across a broad range of topics.  Consequently, there are numerous questions that have been asked to inform Phase 2 consutlations.

Please note - it is not necessary for stakeholders to provide a response to all of the questions posed.  You are invited to respond to any or all questions that relate to your area of interest and understanding.

It is strongly recommended that you read the Consultation Paper before commencing.

Unless otherwise indicated, responses may be published on the Department of Health website for the public to view. 


  • Aboriginal and Torres Strait Islander People
  • Seniors
  • Men
  • Women
  • Carers and guardians
  • Families
  • Parents
  • Young people
  • Non-government organisations
  • State government agencies
  • Commonwealth agencies
  • Local governments
  • Health professionals
  • Health workforce
  • General public
  • Community groups
  • Businesses
  • Contracted Service Providers
  • BPRU staff
  • Graduates
  • Online and Publications staff
  • Secretariat
  • PCCD
  • Health staff
  • HPRG (TGA) Staff
  • Prescription medicines
  • Complementary medicines
  • Over-the-counter medicines
  • Medical Devices & IVDs
  • Biogicals
  • Other


  • Health technology
  • Legislation
  • Women's health
  • Children's health
  • Learning and development
  • Environmental health
  • Strategic Policy
  • Policy Development